Shyam Unniraman

Title: Shyam Unniraman: Innovator in Cancer Immunotherapy

Introduction

Shyam Unniraman is a prominent inventor based in Newton, MA (US). He has made significant contributions to the field of cancer immunotherapy, holding a total of 5 patents. His work focuses on developing innovative solutions to enhance anti-tumor immunity.

Latest Patents

One of his latest patents involves anti-PD-L1 cancer immunotherapy antibodies. This patent provides compositions and methods related to or derived from anti-PD-L1 antibodies with antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC) activities. Specifically, it includes fully human antibodies that bind to PD-L1, along with PD-L1-binding antibody fragments, derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Another notable patent is for rationally designed protein compositions. This innovation relates to a fusion protein that combines a therapeutic antibody with an IL2 mutant. This composition can enhance anti-tumor immunity while directly activating effector cells by IL2 without activating T regulatory cells, making it a promising candidate for cancer prevention and treatment.

Career Highlights

Shyam has worked with several companies, including 1Globe Biomedical Co., Ltd. and 1Globe Health Institute LLC. His experience in these organizations has contributed to his expertise in the field of biomedical research and innovation.

Collaborations

Shyam has collaborated with notable coworkers such as Chiang Jia Li and Hannah Bader. These partnerships have likely enriched his research and development efforts in cancer immunotherapy.

Conclusion

Shyam Unniraman is a dedicated inventor whose work in cancer immunotherapy is paving the way for new treatment options. His innovative patents and collaborations highlight his commitment to advancing medical science.